Imricor Medical Systems (ASX:IMR) was granted a waiver from certain ASX listing rules, effective Tuesday, in order to align its ASX periodic reporting with the reporting requirements in its home jurisdiction in the US, according to a Wednesday Australian bourse filing.

The company said its registration statement on Form 10 became effective on May 17, making it a US public reporting company, subject to the periodic reporting requirements, including requirements to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and periodic reports on Form 8-K with the US Securities and Exchange Commission (SEC).

Imricor will not be required to lodge an Appendix 4D, an Appendix 4E, and an Appendix 4C.

The waiver will cease to apply if Imricor ceases to be subject to an obligation to file Forms 10-K and Forms 10-Q with the US SEC.